x NoneEntity Type
0001536196
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Can-Fite BioPharma Ltd.
Jurisdiction of Incorporation/OrganizationISRAEL 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Can-Fite BioPharma Ltd. 
Street Address 1Street Address 2
 10 BAREKET STREET, KIRYAT MATALON 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 PETACH TIKVA ISRAEL 4951778 972 39241114 



3. Related Persons
Last NameFirst NameMiddle Name
CohnIlan
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
FishmanPnina
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
BornsteinYossi
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
FarbsteinMotti
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
RegevGuy
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SartaniAbraham
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
GoldmanYaacov
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-12-20 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 430 PARK AVENUE 4TH FLOOR
City State/Province/CountryZIP/Postal Code
 NEW YORK NEW YORK 10022
State(s) of Solicitation o All States o Foreign/Non-US
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 10000000 USD o Indefinite
Total Amount Sold $ 10000000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with the immediate exercise of certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 ADSs.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 700000 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 H.C. Wainwright is also entitled to non-accountable expense reimbursement of $75,000 and warrants to purchase an aggregate of 350,000 ADSs exercisable at $2.00 per ADS for five years.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Can Fite BioPharma Charts.
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Can Fite BioPharma Charts.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CANF Message Board. Create One! See More Posts on CANF Message Board See More Message Board Posts

Can-fite Biopharma Ltd. News

Loading Messages....

More Can-fite Biopharma Ltd. News Articles